ACER — Acer Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $19.68m
- $50.19m
Annual cashflow statement for Acer Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -21.3 | -29.4 | -22.9 | -15.4 | -26.2 |
| Depreciation | |||||
| Non-Cash Items | 1.32 | 2.67 | 2.71 | 1.72 | 3.32 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.35 | -2.82 | 3.08 | 13.5 | -7.4 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -16.6 | -29.5 | -17 | -0.135 | -30.3 |
| Capital Expenditures | -0.096 | -0.179 | -0.011 | -0.055 | -0.171 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | — | — | — | — |
| Sale of Business | |||||
| Cash from Investing Activities | -0.096 | -0.179 | -0.011 | -0.055 | -0.171 |
| Financing Cash Flow Items | — | — | — | — | -0.398 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 42.7 | 0.092 | 10.7 | 7.14 | 20 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 26 | -29.6 | -6.32 | 6.95 | -10.4 |